论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Xiang W, Xue H, Wang B, Li Y, Zhang J, Jiang C, Liang F, Pang J, Yu L
Received 3 November 2016
Accepted for publication 6 January 2017
Published 23 February 2017 Volume 2017:11 Pages 513—519
DOI https://doi.org/10.2147/DDDT.S126569
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Dragan Hrncic
Peer reviewer comments 3
Editor who approved publication: Dr James Janetka
Background: Delayed encephalopathy after acute carbon monoxide (CO) poisoning
(DEACMP) commonly occurs after recovering from acute CO poisoning. This study
was performed to assess the efficacy of the combined application of
dexamethasone and hyperbaric oxygen (HBO) therapy in patients with DEACMP.
Patients and methods: A total of 120 patients with DEACMP were recruited and
randomly assigned into the experimental group (receiving dexamethasone
5 mg/day or 10 mg/day plus HBO therapy) and control group (HBO
therapy as monotherapy). Meanwhile, the conventional treatments were provided
for all the patients. We used the Mini-Mental State Examination (MMSE) scale to
assess the cognitive function, the National Institutes of Health Stroke Scale
(NIHSS) to assess the neurological function and the remission rate (RR) to
assess the clinical efficacy. Myelin basic protein (MBP) in the cerebrospinal
fluid (CSF) was also measured.
Results: After 4 weeks of treatment, compared to the
control group, the experimental group had a significantly higher remission rate
(P =0.032), a significantly higher
average MMSE score (P =0.037) and a significantly
lower average NIHSS score (P =0.002).
Meanwhile, there was a trend toward better improvement with dexamethasone
10 mg/day, and the level of MBP in the CSF of patients was significantly
lower in the experimental group than in the control group (P <0.0001). The addition of
dexamethasone did not significantly increase the incidence of adverse events.
Conclusion: These results indicate that the combined application
of dexamethasone and HBO therapy could yield better efficacy for patients with
DEACMP and should be viewed as a potential new therapy.
Keywords: hyperbaric oxygen, carbon monoxide,
dexamethasone, myelin basic protein